Processing...
Clinical Trials for Melanoma
Search
Search
There are 157 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
157 trials meet filter criteria.
Sort by:
TrialFetch AI summary: This trial enrolls adults with metastatic or unresectable CD70-expressing cancers (including clear cell renal cell carcinoma and other solid tumors) who have progressed after at least one prior therapy, to receive a lymphodepleting regimen followed by infusion of autologous T cells genetically engineered with an anti-CD70 chimeric antigen receptor targeting CD70-positive tumor cells, plus high-dose aldesleukin (IL-2) post-infusion.
ClinicalTrials.gov ID: NCT02830724
TrialFetch AI summary: This trial enrolls adults with unresectable locally advanced or metastatic solid tumors—including colorectal, triple-negative breast, melanoma, and ovarian cancer—who have progressed on or cannot receive standard therapies, to receive NM1F (a PVRIG/CD112R immune checkpoint inhibitor) alone or in combination with pembrolizumab. Key exclusions are active CNS involvement, prior PVRIG/CD226-axis therapy, and significant comorbidities.
ClinicalTrials.gov ID: NCT05746897
TrialFetch AI summary: Adults with locally advanced/metastatic c‑Kit–expressing solid tumors (including GIST, SCLC, adenoid cystic carcinoma, uveal melanoma, NETs, chromophobe or clear‑cell RCC) who have progressed after or are ineligible/intolerant to standard therapy receive NN3201, an IV c‑Kit (CD117)–targeted antibody‑drug conjugate delivering MMAE every 3 weeks. Expansion cohorts include GIST (post‑imatinib), SCLC, and other c‑Kit–positive tumors to assess safety and preliminary efficacy.
ClinicalTrials.gov ID: NCT06805825
TrialFetch AI summary: Adults with metastatic melanoma, colorectal cancer, pancreatic ductal adenocarcinoma, or head and neck squamous cell carcinoma harboring MAPK-pathway mutations and no suitable standard options receive oral IPN01194 monotherapy, an ERK1/2 (MAPK1/3) inhibitor targeting the terminal RAS–RAF–MEK–ERK pathway. Dose-escalation identifies two doses, followed by randomized expansion in a single tumor type to assess activity.
ClinicalTrials.gov ID: NCT06305247
TrialFetch AI summary: Adolescents and adults (12–50) with histologically confirmed solid tumors metastatic to the lungs, ECOG ≤2 and adequate organ/pulmonary function, receive on‑site aerosolized gemcitabine via nebulizer twice weekly in 28‑day cycles, including those previously treated with systemic gemcitabine. Gemcitabine is a nucleoside analog prodrug that inhibits ribonucleotide reductase and DNA synthesis; trial excludes active asthma or significant pulmonary symptoms and seeks to define pulmonary MTD and preliminary activity.
ClinicalTrials.gov ID: NCT03093909
TrialFetch AI summary: Adults with metastatic/unresectable melanoma (PD‑1–refractory or PD‑1–naïve) or metastatic clear‑cell RCC refractory to PD‑1/PD‑L1–based therapy receive pembrolizumab (PD‑1 blockade) combined with high‑dose aldesleukin/IL‑2 (T‑cell activation) given inpatient. Single‑arm design aims to improve objective response; excludes significant autoimmune disease, prior severe irAEs, active infection, or major cardiopulmonary compromise.
ClinicalTrials.gov ID: NCT05155033
TrialFetch AI summary: Adults with advanced/metastatic solid tumors after standard therapy receive REGN10597, an intravenously delivered anti–PD-1–IL2RA–IL2 fusion protein designed to target IL-2 signaling to PD-1–positive activated T cells while limiting systemic IL-2 effects; expansion cohorts enroll melanoma and clear-cell RCC. Key exclusions include prior IL-2/IL-15/IL-7 therapy, recent checkpoint inhibitors or systemic therapy, active immune-related AEs, significant autoimmune disease, or need for systemic immunosuppression.
ClinicalTrials.gov ID: NCT06413680
TrialFetch AI summary: Adults with measurable metastatic uveal melanoma (ECOG 0–1), including those with small stable brain mets, receive nonmyeloablative lymphodepletion (cyclophosphamide/fludarabine) followed by a single infusion of autologous tumor-infiltrating lymphocytes and high‑dose IL‑2; TILs are expanded from a resected metastasis and act via tumor‑reactive T‑cell–mediated killing augmented by IL‑2. Key exclusions include active infection, significant autoimmune disease, uncontrolled cardiopulmonary disease, HIV/hepatitis, and systemic steroids.
ClinicalTrials.gov ID: NCT03467516
TrialFetch AI summary: Adults with inoperable stage III/IV melanoma that has progressed after prior anti–PD-1 therapy (with prior BRAF-targeted therapy if BRAF V600+) receive high-dose bolus IL-2 (IL-2 receptor agonist) plus low-dose ipilimumab (anti–CTLA-4) followed sequentially by nivolumab (anti–PD-1), with up to three repeatable courses. Excludes active brain metastases and requires ECOG 0–1 and adequate cardiac/pulmonary function given HD IL-2 toxicity.
ClinicalTrials.gov ID: NCT04562129
TrialFetch AI summary: Pediatric trial of pembrolizumab (anti–PD-1 monoclonal antibody) monotherapy for children/adolescents with advanced melanoma (currently enrolling ages ≥12–≤18) and biomarker-selected solid tumors (MSI-H or TMB ≥10 mut/Mb), plus a cohort for relapsed/refractory classic Hodgkin lymphoma (ages 3–<18) and an adjuvant cohort for resected high-risk melanoma (ages 12–<18). Key exclusions include prior PD-1/PD-L1/CTLA-4 therapy and active CNS metastases or autoimmune disease; dosing is IV q3 weeks (2 mg/kg, max 200 mg).
ClinicalTrials.gov ID: NCT02332668